<DOC>
	<DOCNO>NCT00867490</DOCNO>
	<brief_summary>This study ass safety efficacy aliskiren plus hydrochlorothiazide ( HCTZ ) patient achieve control blood pressure level treatment another specify antihypertensive medication . There optional study extension first eligible 60 patient want participate contains triple therapy amlodipine 5 mg aliskiren 300 mg plus HCTZ 25 mg .</brief_summary>
	<brief_title>Safety Efficacy Aliskiren + Hydrochlorothiazide ( ± Amlodipine 5 mg ) Patients With Moderate Hypertension</brief_title>
	<detailed_description>Title study extension : An open-label , multicenter extension evaluate efficacy safety 4 week therapy amlodipine 5 mg aliskiren 300 mg plus HCTZ 25 mg hypertensive patient adequately respond 4 week therapy combination candesartan 32 mg plus hydrochlorothiazide 25 mg follow aliskiren 300mg plus hydrochlorothiazide 25 mg</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Inclusion Criteria Core Study : Patients mean sit diastolic blood pressure ≥ 100 mmHg &lt; 110 mmHg Inclusion criterion Extension : msSBP ≥ 140 mm Hg and/or msDBP ≥ 90 mm Hg Visit 5 core study Exclusion Criteria Core Study : Patients mean diastolic blood pressure ≥ 110 mmHg mean systolic blood pressure ≥ 180 mmHg Patients prior stroke , hypertensive encephalopathy heart attack Patients type 1 diabetes mellitus Patients type 2 diabetes mellitus poor glucose control Exclusion criterion Extension : Premature discontinuation core study failure comply core study protocol History hypersensitivity study drug drug similar chemical structure , know suspected contraindication diuretic describe SmPC ( particularly amlodipine 5 mg ) , e.g . severe hypotension , shock include cardiogenic shock , obstruction impair flow leave ventricle ( e.g . significant aortic stenosis ) Any patient investigator decides participate extension study medical reason Other protocoldefined inclusion/exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>aliskiren</keyword>
	<keyword>cardiovascular disease</keyword>
</DOC>